PMID-22950504 – Toxicity by NSAIDs Counteraction by Stable Gastric Pentadecapeptide BPC 157
Sikiric P et al. "Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157," Current Pharmaceutical Design, 2013;19(1):76-83. doi:10.2174/13816128130111
Quick Reference
| Property | Value |
|---|---|
| PMID | 22950504 |
| DOI | 10.2174/13816128130111 |
| Year | 2013 |
| Journal | Current Pharmaceutical Design |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | Review of preclinical studies on BPC 157 vs. NSAID toxicity |
| Peptide(s) Studied | BPC-157 |
Key Findings
- Comprehensive review of BPC 157 as an "antidote" against multiple forms of NSAID toxicity
- BPC 157 counteracts GI toxicity (gastric ulcers, intestinal lesions), hepatotoxicity, and encephalopathy caused by NSAIDs
- Effective against both COX-1 and COX-2 selective NSAIDs (aspirin, diclofenac, celecoxib, etc.)
- Protection observed regardless of whether BPC 157 is given before, during, or after NSAID administration
- Mechanism involves NO-system modulation and prostaglandin-independent pathways
- Positions BPC 157 as a potential novel gastroprotective agent distinct from PPIs and misoprostol
Study Design
Narrative review of the Sikiric group's preclinical database on BPC 157 vs. NSAID-induced organ damage. Covers studies using multiple NSAIDs across various animal models with different routes of BPC 157 administration.
Limitations
- All evidence is preclinical (animal and in vitro); no human data
- Single-group evidence: virtually all reviewed studies are from the Sikiric laboratory
- Mechanism of action not fully elucidated at the molecular level
- Published over a decade ago; some findings may have been updated by more recent work
Clinical Relevance
Establishes the theoretical basis for BPC 157 as a gastroprotective agent for NSAID users. The ability to counteract multi-organ NSAID toxicity (not just GI) is distinctive. Key safety reference — the review also documents that BPC 157 itself showed no toxicity at any dose tested. Practically relevant given the large population of chronic NSAID users at risk for GI complications.
Related
#research #narrative-review #evidence-level-V